Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma-Reference-Cited by-同舟云学术

Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma

Published:2014-03-07 Issue:3 Volume:165 Page:375-381
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Tuscano Joseph M.¹²,Dutia Mrinal¹,Chee Karen³,Brunson Ann¹,Reed-Pease Christine¹,Abedi Mehrdad¹,Welborn Jeanna¹,O'Donnell Robert T.¹²

Affiliation:

1. UC Davis Cancer Center; Sacramento CA USA

2. Veteran's Administration Northern California Healthcare System; Martinez CA USA

3. California Cancer Care; San Mateo CA USA

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.12755/fullpdf

Reference32 articles.

1. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte;Brice;Journal of Clinical Oncology,1997

2. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene;Cartron;Blood,2002

3. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group;Cheson;Journal of Clinical Oncology,1999

4. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-α-2a;Davis;Clinical Cancer Research,2000

5. Lenalidomide overcomes FCRG3A-mediated resistance to rituximab in patients with relapsed/refractory indolent non-Hodgkin's lymphoma: a correlative analysis of a phase 2 study;Dutia;Blood (ASH Annual Meeting Abstracts),2010

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lenalidomide, rituximab (R ² ), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma;Leukemia & Lymphoma;2024-03-08

2. Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive After Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study;HemaSphere;2023-02-21

3. Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis;Clinical Cancer Research;2022-06-21

4. Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review;Cancers;2022-05-17

5. Unveiling the Role of the Tumor Microenvironment in the Treatment of Follicular Lymphoma;Cancers;2022-04-26